Coherus BioSciences Inc (CHRS) Actualités

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved...

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter...

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities